成长 长青 共利 沪士电子股份有限公司 2022 年度报告全文 | 第一节 | 重要提示、备查文件和释义 | -------------------------------------------------------------- | - | 1 - | | --- | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | ------------------------------------------------------------------ | | 4 - | | 第三节管理层讨论与分析 | | --------------------------------------------------------------------------- | | 7 - | | 第四节 | 公司治理 | ---------------------------------------------------------------------------------- - | | 32 - | | 第五节 | 环境和社会责任 | ------------------ ...

| 第一节 | 重要提示、备查文件和释义 ------------------------------------------------------------------1 | | | --- | --- | --- | | 第三节 | 管理层讨论与分析 ---------------------------------------------------------------------------- | 7 | | 第八节 | 财务报告 --------------------------------------------------------------------------------------83 | | 成长 长青 共利 沪士电子股份有限公司 2024 年度报告 第一节 重要提示、备查文件和释义 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证年度报告的内容真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司所有董事均已出席审议本报告的董事会会议。公司负责人陈梅芳女士、主管会计工 作负责人朱碧霞女士及会计机构负责人李可欣女士声明：保证 ...

| 第一节 | 重要提示、备查文件和释义 | ----------------------------------------------------------------------- | | 1 - | | --- | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | -------------------------------------------------------------------------- | | 4 - | | 第三节管理层讨论与分析 | | ---------------------------------------------------------------------------------- | - | 7 - | | 第四节 | 公司治理 | -------------------------------------------------------------------------------------------- - | 36 | - | | 第五节 | 环境和社会责任 | ---------------- ...

北京君正集成电路股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 北京君正集成电路股份有限公司 2025 年第三季度报告 证券代码：300223 证券简称：北京君正 公告编号：2025-068 3.第三季度财务会计报告是否经过审计 □是 否 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 1 北京君正集成电路股份有限公司 2025 年第三季度报告 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 重要内容提示： | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 1,187,388,497.87 | 8.50% | 3,436,500,879.19 | 7.35% | | 归属于上市公司股东 | ...

天域生物科技股份有限公司 2025 年第三季度报告 证券代码：603717 证券简称：天域生物 天域生物科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 123,298,080.72 | -38.69 | 535,601,036.79 | -14.23 | | 利润总额 | -19,173,115.50 | -254.11 | 13,461,512.93 ...

2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 江阴电工合金股份有限公司 2025 年第三季度报告 证券代码：300697 证券简称：电工合金 公告编号：2025-042 江阴电工合金股份有限公司 3.第三季度财务会计报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 862,647,713.57 | 43.08% | 2,293,439,830.06 | 25.11% | | 归 ...

Financial Performance - In Q3 2025, the company achieved revenue of RMB 17.162 billion, a quarter-on-quarter increase of 6.9%[3] - For the first three quarters of 2025, the company reported revenue of RMB 49.510 billion, an 18.2% increase year-on-year[5] - The total profit for Q3 2025 was RMB 2.557 billion, a 47.9% increase compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2025 was RMB 1.517 billion, reflecting a year-on-year growth of 43.1%[5] - Total revenue for the first three quarters of 2025 reached RMB 49,510,416 thousand, an increase of 18.9% compared to RMB 41,878,720 thousand in the same period of 2024[25] - Operating profit for the first three quarters of 2025 was RMB 6,189,760 thousand, compared to RMB 3,552,445 thousand in 2024, representing a significant increase of 74.0%[25] - The company reported a net profit of RMB 5,770,359 thousand for the first three quarters of 2025, compared to RMB 3,232,660 thousand in 2024, marking an increase of 78.5%[25] - Net profit for the first three quarters of 2025 reached CNY 5,770,359 thousand, a significant increase from CNY 3,232,660 thousand in the same period of 2024, representing a growth of approximately 78.8%[26] - The net profit attributable to shareholders of the parent company was CNY 3,818,071 thousand, up from CNY 2,706,192 thousand in 2024, marking an increase of about 41.2%[26] - Total comprehensive income for the first three quarters of 2025 was CNY 3,658,625 thousand, compared to CNY 1,143,034 thousand in 2024, indicating a growth of approximately 219.5%[26] Margins and Utilization - The gross margin for Q3 2025 was 25.5%, up 4.8 percentage points from the previous quarter[3] - The capacity utilization rate increased to 95.8%, a rise of 3.3 percentage points quarter-on-quarter[3] - The company expects Q4 2025 revenue to remain flat to grow by 2% quarter-on-quarter, with a gross margin guidance of 18% to 20%[4] Research and Development - The R&D expenditure for Q3 2025 was RMB 1.447 billion, accounting for 8.4% of revenue, an increase of 0.2 percentage points year-on-year[5] - Research and development expenses for the first three quarters of 2025 were RMB 3,822,453 thousand, slightly down from RMB 3,895,213 thousand in the same period of 2024[25] Cash Flow and Assets - The company's cash and cash equivalents decreased to RMB 28,362,576 thousand as of September 30, 2025, down from RMB 48,029,335 thousand at the end of 2024[21] - Cash inflow from operating activities totaled CNY 52,107,168 thousand, compared to CNY 48,441,439 thousand in 2024, reflecting an increase of about 13.7%[29] - Cash outflow from investing activities was CNY 55,284,328 thousand in 2025, compared to CNY 54,802,076 thousand in 2024, indicating a slight increase of 0.9%[30] - The cash and cash equivalents at the end of the period were CNY 24,751,153 thousand, down from CNY 25,596,576 thousand in 2024, a decrease of approximately 3.3%[30] Shareholder Information - The company has issued a total of 7,999,709,148 shares, with 6,000,146,599 shares listed on the Hong Kong Stock Exchange, accounting for 75.00% of the total share capital[17] - The top shareholder, HKSCC NOMINEES LIMITED, holds 60.77% of the shares, totaling 4,861,299,784 shares[16] - The total number of ordinary shareholders at the end of the reporting period is 336,231, with 325,962 being A-share holders[16] Liabilities and Equity - Total liabilities decreased to RMB 116,231,851 thousand as of September 30, 2025, from RMB 124,307,508 thousand at the end of 2024, a reduction of 6.5%[23] - Shareholders' equity increased to RMB 235,136,565 thousand as of September 30, 2025, compared to RMB 229,107,788 thousand at the end of 2024, reflecting a growth of 2.6%[23] Other Financial Metrics - The total non-recurring gains and losses for the current period amount to CNY 244,059,000, with a year-to-date total of CNY 641,200,000[10] - The investment income from joint ventures and associates attributable to the group is CNY 5,923,000 for the year-to-date[11] - The company reported a decrease in net profit of CNY 145,549,000 due to passive dilution from joint ventures under international financial reporting standards[13] - The fair value changes of financial assets held by joint ventures and associates are not specified in the current report[11] - The company received government subsidies closely related to its normal business operations amounting to CNY 182,045,000 for the current period[10]

Financial Performance - The total operating revenue for the first nine months of 2025 reached RMB 1.115 billion, an increase of 59.85% compared to the same period last year, with a gross margin of 88.8%, up 2.8 percentage points from 86.0%[4] - Sales revenue from the core product, Orelabrutinib (宜诺凯®), amounted to RMB 1.010 billion for the first nine months of 2025, representing a year-on-year growth of 45.77%[5] - The company reported a significant increase in operating revenue, primarily due to the continuous increase in sales volume of a key product, resulting in a substantial cash inflow[12] - Total revenue for the first three quarters of 2025 reached CNY 1,115,328,393.86, a significant increase of 60% compared to CNY 697,748,228.93 in the same period of 2024[21] - The company's total revenue from drug sales for the first nine months of 2025 was RMB 1.024 billion, an increase of 47.38% year-on-year[7] Expenses and Losses - The net loss for the first nine months of 2025 was RMB 72 million, a reduction of 74.78% compared to the same period last year[4] - Research and development expenses totaled RMB 676 million for the first nine months of 2025, accounting for 60.61% of operating revenue, a decrease of 27.53 percentage points year-on-year[7] - The net loss for the first three quarters of 2025 was CNY 71,950,523.03, an improvement from a net loss of CNY 285,317,584.04 in the same period of 2024[22] - The company experienced a net loss attributable to shareholders, with basic and diluted earnings per share showing a decline compared to the same period last year[12] - The company reported a basic and diluted earnings per share of CNY -0.04 for the first three quarters of 2025, compared to CNY -0.16 in 2024[22] Cash Flow and Assets - As of September 30, 2025, the company held approximately RMB 7.759 billion in cash and cash equivalents, enabling continued acceleration of pipeline project development[6] - The company's cash and cash equivalents increased to CNY 6,820,269,250.58 as of September 30, 2025, compared to CNY 6,240,825,867.22 at the end of 2024[19] - The total assets as of September 30, 2025, were CNY 9,523,812,210.96, up from CNY 9,407,493,740.91 at the end of 2024[20] - The total cash and cash equivalents at the end of the period decreased to CNY 4,382,410,146.31 from CNY 4,949,637,182.02 year-over-year[24] - The company reported a cash outflow of CNY 1,389,806,235.54 from operating activities, compared to CNY 1,220,717,440.28 in the previous year[24] Shareholder Information - The total number of shares issued by the company is 1,764,643,952, with 1,496,284,235 shares (approximately 84.79%) listed in Hong Kong and 268,359,717 shares (approximately 15.21%) listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board[13] - HKSCC NOMINEES LIMITED holds 892,010,619 shares, representing 50.549% of the total shares[16] - HHLR Fund, L.P. and its concerted parties hold 208,671,222 shares, accounting for 11.8251% of the total shares[17] - Sunny View Holdings and the Zhao family hold 144,817,893 shares, which is 8.2066% of the total shares[17] - The top ten shareholders' holdings were disclosed, with HKSCC NOMINEES LIMITED being the largest shareholder[16] Research and Development - Orelabrutinib was approved for a new indication in April 2025 for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients[5] - Research and development expenses amounted to CNY 676,047,531.53, compared to CNY 614,983,375.71 in the previous year, indicating a focus on innovation[21] - The company is actively pursuing market expansion and innovation strategies, as indicated by the increase in R&D spending and overall revenue growth[21] Government Support - The company received government subsidies amounting to RMB 28.17 million for the year-to-date period, contributing to non-operating income[10] Cash Flow Activities - The cash inflow from operating activities increased significantly, driven by higher cash receipts from product sales and upfront payments from licensing agreements[12] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 1,305,468,105.49, a significant increase of 47% compared to CNY 887,581,258.65 in the same period of 2024[24] - The net cash flow from operating activities was negative at CNY -84,338,130.05, an improvement from CNY -333,136,181.63 in the previous year[24] - Cash inflow from investment activities reached CNY 8,250,925,494.08, up from CNY 4,648,580,477.88, marking a growth of 77% year-over-year[24] - The net cash flow from investment activities was CNY -321,499,940.72, a decline from CNY 1,358,936,924.87 in the same period last year[24] - Cash inflow from financing activities totaled CNY 363,355,524.15, down from CNY 1,083,202,214.00 in the previous year[24] - The net cash flow from financing activities was CNY 138,210,016.73, a recovery from CNY -261,692,786.26 in the same period of 2024[24] Accounting Standards - The company did not apply new accounting standards for the year 2025[25]

Financial Performance - Total revenue for Q3 2025 reached CNY 10,076,964 thousand, representing a 41.1% increase compared to the same period last year[4] - Net profit attributable to shareholders for the year-to-date period was CNY 1,138,596 thousand, with a significant increase driven by product revenue growth and improved operational efficiency[12] - Adjusted operating profit for the first three quarters of 2025 was CNY 5,543 million, a substantial increase from CNY 520 million in the same period last year[14] - Total revenue for the first three quarters of 2025 reached RMB 27,595,233 thousand, a 44.2% increase from RMB 19,135,857 thousand in the same period of 2024[23] - Operating profit for the first three quarters of 2025 was RMB 1,544,645 thousand, compared to a loss of RMB 3,410,742 thousand in the first three quarters of 2024[24] - Net profit for the first three quarters of 2025 was RMB 1,138,596 thousand, a significant recovery from a net loss of RMB 3,686,694 thousand in the same period of 2024[24] Earnings Per Share - The company reported a basic earnings per share of CNY 0.48 for Q3 2025, with a year-to-date basic earnings per share of CNY 0.81[4] - The diluted earnings per share for Q3 2025 was CNY 0.46, with a year-to-date diluted earnings per share of CNY 0.77[5] - The company reported a basic earnings per share of RMB 0.81 for the first three quarters of 2025, recovering from a loss of RMB 2.71 in the same period of 2024[24] Research and Development - Research and development expenses totaled CNY 3,881,607 thousand for the quarter, accounting for 38.5% of total revenue, a decrease of 1.9 percentage points from the previous year[5] - Research and development expenses for the first three quarters of 2025 were RMB 11,159,244 thousand, compared to RMB 10,165,926 thousand in the same period of 2024[23] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 4,281,906 thousand, reflecting increased cash inflow due to higher product revenue[12] - In the first three quarters of 2025, the cash inflow from operating activities reached CNY 29,314,279 thousand, a 48.5% increase compared to CNY 19,749,714 thousand in the same period of 2024[26] - The net cash flow from operating activities for the first three quarters of 2025 was CNY 4,281,906 thousand, a significant recovery from a net outflow of CNY -1,841,136 thousand in 2024[26] - Cash received from sales of goods and services was CNY 28,964,747 thousand in 2025, compared to CNY 19,425,796 thousand in 2024, marking a 49.2% increase[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 54,075,712 thousand, a 26.2% increase from the end of the previous year[5] - Total assets as of September 30, 2025, amounted to RMB 54,075,712 thousand, up from RMB 42,834,708 thousand at the end of 2024[22] - Total liabilities increased to RMB 24,740,766 thousand as of September 30, 2025, compared to RMB 18,659,486 thousand at the end of 2024[22] - The company’s total current assets reached RMB 40,103,859 thousand, up from RMB 28,906,961 thousand at the end of 2024[22] Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 36,172, with no preferred shareholders having restored voting rights[16] - The total number of circulating shares was 1,438,083,590, with 92% (1,323,028,330 shares) being foreign circulating shares and 8% (115,055,260 shares) being domestic RMB shares[15] - The largest shareholder, Amgen, held 246,269,426 shares, representing 17.12% of total shares[16] - Baker Brothers Life Sciences, L.P. and its affiliates held 115,666,055 shares, accounting for 8.04% of total shares[16] - Capital Research and Management Company and its affiliates owned 77,379,268 shares, which is 5.38% of total shares[16] - The top ten shareholders did not participate in margin financing or securities lending activities[20] - The company has not disclosed any related party relationships among the top shareholders[18] Risks and Challenges - The company emphasizes the high risks associated with the biopharmaceutical industry, including long R&D cycles and regulatory uncertainties[20] - The company’s ability to achieve commercial success for its drug candidates is contingent on various factors, including regulatory approvals and clinical trial outcomes[20] - The company warns investors about potential risks that could significantly impact its future business plans and financial performance[20] Investment Activities - Cash outflow for investment activities totaled CNY 10,625,977 thousand in 2025, compared to CNY 2,975,746 thousand in 2024, indicating a substantial increase in investment expenditures[26] - The company received CNY 1,310,443 thousand from investment in 2025, a significant increase from CNY 303,069 thousand in 2024[26] Financing Activities - The net cash flow from financing activities was CNY 6,400,313 thousand in 2025, up from CNY 1,192,649 thousand in 2024, reflecting increased financing efforts[26] - The company reported a cash inflow of CNY 6,288,368 thousand from other financing activities in 2025, indicating new financing sources[26] Cash and Cash Equivalents - Cash and cash equivalents rose to RMB 13,933,606 thousand from RMB 12,279,419 thousand year-over-year[22] - The total cash and cash equivalents at the end of Q3 2025 amounted to CNY 13,557,097 thousand, an increase from CNY 12,179,613 thousand at the end of Q3 2024[26] - The impact of exchange rate changes on cash and cash equivalents was CNY 95,540 thousand in 2025, compared to a negative impact of CNY -12,502 thousand in 2024[26]

Financial Performance - The company's operating revenue for the third quarter reached ¥122,610,651.54, representing a year-on-year increase of 94.98%[5] - Net profit attributable to shareholders was ¥22,961,590.93, a significant increase of 175.32% compared to the same period last year[5] - Total operating revenue for the period reached CNY 219,446,400.41, an increase of 23.3% compared to CNY 177,910,871.82 in the previous period[24] - The company reported a net profit of CNY 3,128,394.12 from investments, a significant decrease from CNY 28,465,308.71 in the previous period[24] - The net profit for the current period is -22,182,784.48, compared to -58,846,104.36 in the previous period, showing an improvement[25] - The total comprehensive income for the current period is -22,182,784.48, while it was -58,846,104.36 in the previous period, indicating a significant reduction in losses[26] - The basic and diluted earnings per share for the current period are 0.0591, compared to -0.2082 in the previous period, reflecting a positive shift[26] Cash Flow and Assets - The company reported a net cash flow from operating activities of -¥133,802,830.14, indicating a cash outflow increase due to expanded online sales and advertising expenses[5] - Cash inflows from operating activities totaled 226,016,058.21, up from 206,162,660.18 in the previous period[27] - The net cash flow from operating activities is -133,802,830.14, worsening from -22,058,785.11 in the previous period[28] - Cash inflows from investing activities increased to 212,784,754.31 from 38,709,670.67, indicating a strong investment recovery[28] - The net cash flow from investing activities is 155,923,458.76, compared to 35,783,732.52 in the previous period, showing significant improvement[28] - Cash inflows from financing activities decreased to 36,006,080.94 from 106,782,702.08, reflecting reduced borrowing[28] - Cash and cash equivalents decreased to CNY 42,341,959.50 from CNY 120,054,863.07, reflecting a decline of 64.8%[22] - The ending cash and cash equivalents balance is 42,341,959.50, slightly down from 43,520,169.60 in the previous period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,118,559,588.84, up 16.16% from the end of the previous year[5] - Total assets increased to CNY 1,118,559,588.84 from CNY 962,921,879.35, representing a growth of 16.2%[23] - The company's equity attributable to shareholders decreased to CNY 467,325,199.48 from CNY 486,400,658.64, a decline of 3.3%[24] - The company's total liabilities increased due to higher short-term borrowings to support daily operations and increased accounts payable for raw material purchases[10] - Total liabilities rose to CNY 337,061,866.88, compared to CNY 155,767,490.13, reflecting an increase of 116.3%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,760[14] - The largest shareholder, Lanzhou Huanghe Xinseng Investment Co., Ltd., holds 21.50% of shares, totaling 39,931,229 shares[14] - The top ten shareholders include Hunan Yucheng Investment Co., Ltd. with a 5.00% stake, totaling 9,288,300 shares[14] - The company has repurchased 3,764,300 shares, accounting for 2.03% of the total share capital, with a total expenditure of 30 million RMB[17] - The maximum repurchase price was 9.70 RMB per share, with a transaction range between 7.10 RMB and 8.30 RMB per share[17] - The total amount allocated for the share repurchase plan is between 20 million and 30 million RMB[17] - The company has not disclosed any changes in the participation of major shareholders in margin trading activities[16] Business Expansion and Investments - The company expanded its online sales channels, resulting in an increase in sales revenue by ¥39,340,000 from platforms like Douyin[11] - The acquisition of the juice beverage business contributed ¥17,300,000 in revenue since its consolidation[11] - The company increased its advertising and promotional expenses to support online sales, leading to a rise in sales expenses compared to the previous year[11] - The company reported a decrease in research and development expenses, as these activities were integrated into production processes without separate accounting[11] - The company recognized a non-recurring gain of ¥289,508.40 from the acquisition of Wu Zhong Huang He, where the investment cost was less than the fair value of identifiable net assets[6] - A new subsidiary, Huanghe (Chongqing) Beverage Co., Ltd., was established in partnership with Chongqing Chengbiao Agricultural Development Co., Ltd.[18] - The company acquired 50.6329% equity in Yiwang Juice Co., Ltd. for 0 RMB, with a total capital contribution of 26,917,521.60 RMB[19] - The company plans to establish a branch in Shenzhen, which was approved in the board meeting on August 25, 2025[17] Financial Report Status - The financial report for the third quarter has not been audited[30]